Shingrix Vaccination Linked to Lower Dementia Diagnosis

Does the Shingrix Vaccine Reduce Dementia Risk?

The reported analysis followed more than 500,000 older adults and found that people who received Shingrix were 24% less likely to be diagnosed with dementia over four years. This is an association: differences in health, healthcare access, preventive behavior, or underlying illness could partly explain why vaccinated and unvaccinated groups had different outcomes.

Researchers will need to reproduce the finding and determine whether the association persists after accounting for these factors. Longer follow-up is also important because dementia develops gradually, often years before symptoms become clinically apparent. The result therefore supports further investigation rather than using Shingrix as a dementia treatment or guaranteed prevention strategy.

How Could Shingles Vaccination Be Connected to Brain Health?

Shingles occurs when varicella-zoster virus, which remains dormant after chickenpox, reactivates later in life. The illness can cause severe nerve pain and, less commonly, neurological complications. Preventing episodes of viral reactivation could theoretically reduce inflammation or other physiological stresses that may affect vulnerable brains.

Shingrix is a recombinant, adjuvanted vaccine designed to generate a strong immune response against varicella-zoster virus. Scientists are also examining whether vaccination produces broader immune effects that influence neuroinflammation. These hypotheses are biologically plausible, but the new association alone cannot show which mechanism—if any—accounts for the observed difference in dementia diagnoses.

Should Older Adults Get Shingrix to Prevent Dementia?

The US Centers for Disease Control and Prevention recommends two doses of Shingrix for adults aged 50 years and older, as well as for adults aged 19 years and older who are or will be immunocompromised because of disease or therapy. Its established purpose is to prevent shingles and related complications, including postherpetic neuralgia.

The dementia finding may eventually strengthen the broader public-health case for vaccination, but it should not replace proven approaches to protecting cognitive health. Managing blood pressure and diabetes, avoiding tobacco, remaining physically active, addressing hearing loss, and maintaining social engagement are among the modifiable factors supported by wider dementia-prevention evidence.